X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs STRIDES SHASUN LTD - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS STRIDES SHASUN LTD IPCA LABS/
STRIDES SHASUN LTD
 
P/E (TTM) x 28.0 14.1 198.3% View Chart
P/BV x 2.1 1.9 112.4% View Chart
Dividend Yield % 0.2 0.5 43.9%  

Financials

 IPCA LABS   STRIDES SHASUN LTD
EQUITY SHARE DATA
    IPCA LABS
Mar-17
STRIDES SHASUN LTD
Mar-16
IPCA LABS/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs6431,413 45.5%   
Low Rs503848 59.3%   
Sales per share (Unadj.) Rs254.4353.3 72.0%  
Earnings per share (Unadj.) Rs16.123.4 68.7%  
Cash flow per share (Unadj.) Rs29.841.0 72.6%  
Dividends per share (Unadj.) Rs1.005.00 20.0%  
Dividend yield (eoy) %0.20.4 39.5%  
Book value per share (Unadj.) Rs194.6320.4 60.7%  
Shares outstanding (eoy) m126.2089.35 141.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.33.2 70.4%   
Avg P/E ratio x35.748.3 73.8%  
P/CF ratio (eoy) x19.227.6 69.8%  
Price / Book Value ratio x2.93.5 83.5%  
Dividend payout %6.221.4 29.1%   
Avg Mkt Cap Rs m72,300100,988 71.6%   
No. of employees `00013.34.7 283.6%   
Total wages/salary Rs m6,9604,988 139.5%   
Avg. sales/employee Rs Th2,413.56,730.0 35.9%   
Avg. wages/employee Rs Th523.21,063.6 49.2%   
Avg. net profit/employee Rs Th152.4445.5 34.2%   
INCOME DATA
Net Sales Rs m32,10631,564 101.7%  
Other income Rs m2261,212 18.6%   
Total revenues Rs m32,33232,776 98.6%   
Gross profit Rs m4,4485,213 85.3%  
Depreciation Rs m1,7301,573 110.0%   
Interest Rs m2411,803 13.4%   
Profit before tax Rs m2,7033,049 88.7%   
Minority Interest Rs m0127 0.0%   
Prior Period Items Rs m0-27 0.0%   
Extraordinary Inc (Exp) Rs m0-371 0.0%   
Tax Rs m675689 98.1%   
Profit after tax Rs m2,0282,089 97.1%  
Gross profit margin %13.916.5 83.9%  
Effective tax rate %25.022.6 110.6%   
Net profit margin %6.36.6 95.4%  
BALANCE SHEET DATA
Current assets Rs m17,34035,949 48.2%   
Current liabilities Rs m9,55919,402 49.3%   
Net working cap to sales %24.252.4 46.2%  
Current ratio x1.81.9 97.9%  
Inventory Days Days10071 141.5%  
Debtors Days Days57127 44.8%  
Net fixed assets Rs m20,77934,478 60.3%   
Share capital Rs m252894 28.2%   
"Free" reserves Rs m24,49922,601 108.4%   
Net worth Rs m24,55328,632 85.8%   
Long term debt Rs m3,51727,455 12.8%   
Total assets Rs m39,59576,591 51.7%  
Interest coverage x12.22.7 454.3%   
Debt to equity ratio x0.11.0 14.9%  
Sales to assets ratio x0.80.4 196.8%   
Return on assets %5.75.1 112.7%  
Return on equity %8.37.3 113.2%  
Return on capital %10.58.2 128.4%  
Exports to sales %48.648.1 101.1%   
Imports to sales %14.214.5 98.4%   
Exports (fob) Rs m15,61715,192 102.8%   
Imports (cif) Rs m4,5714,565 100.1%   
Fx inflow Rs m15,61716,612 94.0%   
Fx outflow Rs m5,8285,292 110.1%   
Net fx Rs m9,79011,320 86.5%   
CASH FLOW
From Operations Rs m2,764717 385.7%  
From Investments Rs m-1,432-22,284 6.4%  
From Financial Activity Rs m-1,59129,488 -5.4%  
Net Cashflow Rs m-2598,073 -3.2%  

Share Holding

Indian Promoters % 45.9 27.7 165.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 37.8 30.2%  
FIIs % 25.3 8.6 294.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 25.9 67.2%  
Shareholders   36,892 56,241 65.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 17, 2017 03:37 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS